Search results for " Replacement"

showing 10 items of 539 documents

Monitoring of Enzyme Substitution Using the Cholesteryl Octanoate Breath Test

1991

The efficiency of enzyme replacement therapy in pancreatic insufficiency is usually judged on the grounds of clinical improvement and the effect on steatorrhea: treatment is thought to be successful if steatorrhea is abolished or, at least, reduced. In the majority of patients, the amount of enzyme necessary to alleviate steatorrhea can be reduced if lipase is protected against acidic inactivation either by blocking H2 secretion of the stomach or by protecting enzymes by pH-sensitive enteric coating. However, steatorrhea is frequently not abolished and a differential treatment may be necessary in each patient.

chemistry.chemical_classificationBreath testmedicine.medical_specialtymedicine.diagnostic_testbiologyGastric emptyingStomachdigestive oral and skin physiologynutritional and metabolic diseasesEnzyme replacement therapyEnteric coatingdigestive system diseasesSteatorrheaEnzymemedicine.anatomical_structureEndocrinologychemistryBiochemistryInternal medicinemedicinebiology.proteinLipasemedicine.symptommedicine.drug
researchProduct

Crystal structure of the bifunctional soybean Bowman-Birk inhibitor at 0.28-nm resolution. Structural peculiarities in a folded protein conformation.

1996

The Bowman-Birk inhibitor from soybean is a small protein that contains a binary arrangement of trypsin-reactive and chymotrypsin-reactive subdomains. In this report, the crystal structure of this anticarcinogenic protein has been determined to 0.28-nm resolution by molecular replacement from crystals grown at neutral pH. The crystal structure differs from a previously determined NMR structure [Werner, M. H. & Wemmer, D. E. (1992) Biochemistry 31, 999-1010] in the relative orientation of the two enzyme-insertion loops, in some details of the main chain trace, in the presence of favourable contacts in the trypsin-insertion loop, and in the orientation of several amino acid side chains. The p…

chemistry.chemical_classificationModels MolecularMagnetic Resonance SpectroscopyStereochemistryProtein ConformationMolecular Sequence DataWaterCrystal structureCrystallography X-RayBiochemistryProtein tertiary structureProtein Structure SecondaryAmino acidCrystallographychemistry.chemical_compoundKineticsProtein structurechemistrySide chainChymotrypsinProtein foldingMolecular replacementAmino Acid SequenceBifunctionalTrypsin Inhibitor Bowman-Birk SoybeanEuropean journal of biochemistry
researchProduct

Klīnisko rezultātu novērtēšana pēc ceļa locītavu endoprotezēšanas

2016

Novecojušā sabiedrībā ar pieaugošo dzīves ilgumu, pieaug arī pieprasījums pēc pilnīgas ceļa locītavas aizvietošanas. Tajā pašā laikā cilvēki sešdesmit un septiņdesmit gadu vecumā ir daudz aktīvāki kā iepriekšējā paaudze un prasīgāki attiecībā uz mobilitāti. Klīniskais iznākums pilnīgai ceļa locītavas aizvietošanai ir mainīgs, jo viens no pieciem pacientiem nav apmierināts pēc operācijas. Ir vairāki gan ar pacientu saistīti, gan ar veselības aprūpi saistīti faktori, kas ietekmē pilnīgas ceļa locītavas aizvietošanas iznākumu. Mērķis ir apskatīt publicēto literatūru un parādīt gan ar pacientu, gan ar veselības aprūpi saistītos faktorus, kas ietekmē pilnīgas ceļa locītas aizvietošanas iznākumu.

clinical outcome after knee replacementKlīniskā rezultāts pēc ceļa locītavasortopēdijaMedicīnaorthopaedics
researchProduct

A new replacement name for the fossil spider Veterator Petrunkevitch, 1963 (Arthropoda: Arachnida: Araneae)

2021

A junior homonym was detected in the genera of fossil Araneae and the following replacement name is proposed within the family Trochanteriidae: Neoveterator Ceccolini & Cianferoni nom. nov. pro Veterator Petrunkevitch, 1963 nec Laws, 1944. Eight new combinations (comb. nov.) are proposed.

combinatio nova fossil araneae nomen novum replacement nameSpiderbiologyNomen novumPaleontologyZoologyTrochanteriidaebiology.organism_classificationQE701-760Homonym (biology)Combinatio novaNomen novumReplacement nameFossil Araneae
researchProduct

Enzyme replacement and gene therapy for mucopolysaccharidoses: current progress and future directions

2015

Introduction: Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes that are responsible for the stepwise degradation of complex carbohydrates, the glycosaminoglycans. Whereas in the past the treatment of MPS consisted mainly of palliative care, enzyme replacement therapy (ERT) is now possible for some MPS disorders, and in the future many other therapeutic options will become available.Areas covered: This review, based on personal experience and the currently available literature, will give an overview on the efficacy and limitations of ERT and will discuss new therapeutic approaches, such as anti-inflammatory drugs, substrate reduction therapy, ch…

congenital hereditary and neonatal diseases and abnormalitiesPalliative carebusiness.industryHealth PolicyGenetic enhancementmedicine.medical_treatmentnutritional and metabolic diseasesLysosomal storage disordersHematopoietic stem cell transplantationEnzyme replacement therapyBioinformaticsImmunologymedicinePharmacology (medical)Substrate reduction therapybusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)Expert Opinion on Orphan Drugs
researchProduct

Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany

2015

Enzyme replacement therapy (ERT) has been shown to improve outcome in classical infantile Pompe disease. The purpose of this study was to assess mortality, morbidity, and shortcomings of ERT in a larger cohort of patients treated outside clinical trials. To accomplish this, we retrospectively analyzed the data of all 23 subjects with classical infantile Pompe disease having started ERT in Germany between January 2003 and December 2010.Ten patients (43%) deceased and four others (17%) became ventilator dependent. Seven infants (30.5%) made no motor progress at all, while seven (30.5%) achieved free sitting, and nine (39%) gained free walking. Besides all the seven patients (100%) attaining n…

congenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtybusiness.industryMEDLINEnutritional and metabolic diseases610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.disease1301 Biochemistry Genetics and Molecular Biology (miscellaneous)ArticleClinical trial2712 Endocrinology Diabetes and Metabolism10036 Medical Clinic2724 Internal MedicineCohortmedicineGlycogen storage diseasebusiness
researchProduct

Systemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic stem cell transplantation or enzyme replacement therapy - a rev…

2010

The management of mucopolysaccharidosis (MPS) is focused on the multi-organ, sometimes life-threatening, clinical manifestations that occur over time. In the past, the limited, symptom-based treatment options led physicians to adopt a palliative approach towards individual disease-associated complications. The availability of systemic treatments such as haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) has created a better prognosis for MPS patients, particularly when initiated early in life. As part of an integrated management approach, these therapies could be valuable in managing the ocular features that are present in many children with MPS. HSCT has b…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryMucopolysaccharidosismedicine.medical_treatmentEye diseasenutritional and metabolic diseasesEnzyme replacement therapyHematopoietic stem cell transplantationmedicine.diseaseeye diseasesSurgeryTransplantationOphthalmologymedicineOptic nervesense organsStem cellmedicine.symptomIntensive care medicinebusinessClinical & Experimental Ophthalmology
researchProduct

Management of Acute Kidney Injury and Extracorporeal Blood Purification Therapies During the COVID-19 Pandemic: The Italian SIN–SIAARTI Joint Survey …

2022

Background and AimThe novel coronavirus disease 2019 remains challenging. A large number of hospitalized patients are at a high risk of developing AKI. For this reason, we conducted a nationwide survey to assess the incidence and management of AKI in critically ill patients affected by the SARS-CoV-2 infection.MethodsThis is a multicenter, observational, nationwide online survey, involving the Italian Society of Nephrology and the critical care units in Italy, developed in partnership between the scientific societies such as SIN and SIAARTI. Invitations to participate were distributed through emails and social networks. Data were collected for a period of 1 week during the COVID-19 pandemic…

critical careCOVID-19; acute kidney injury; blood purification; critical care; renal replacement therapy; surveys and questionnairesacute kidney injurysurveys and questionnairesCOVID-19blood purificationGeneral Medicineurologic and male genital diseasesrenal replacement therapyFrontiers in Medicine
researchProduct

219 Incidence Testing of Hunter Syndrome in A Population at Risk - First Results of A Binational Screening Programme

2012

Background Hunter syndrome (Mucopolysaccharidosis type II; X-linked inheritance; prevalence rate in Europe approximately 1:77000 male newborns) is a rare, progressive, multisystemic disease, caused by deficiency of the lysosomal enzyme Iduronate-2-sulfatase. Due to the very heterogeneous phenotype Hunter syndrome is often not diagnosed before pre-school age. This is unfortunate, because patients would significantly benefit from the earliest possible start of treatment containing enzyme replacement therapy. Early screening methods are possible, but due to the rarity of this disease they are too expensive to be performed in all newborns. An at-risk patient population screening provides opport…

education.field_of_studyPediatricsmedicine.medical_specialtybusiness.industryIncidence (epidemiology)PopulationPrevalenceHunter syndromeEnzyme replacement therapymedicine.diseaseUmbilical herniaPediatrics Perinatology and Child Healthmedicinemedia_common.cataloged_instanceEuropean unionMucopolysaccharidosis type IIbusinesseducationmedia_commonArchives of Disease in Childhood
researchProduct

Effects of combined hormone replacement therapy or its effective agents on the IGF-1 pathway in skeletal muscle.

2010

Objectives To investigate the effects of combined hormone replacement therapy (HRT) and its effective agents on the IGF-1 signaling pathway. Design and methods To examine the effects of HRT on skeletal muscle in vivo, we utilized pre- and post-intervention samples from a randomized double blinded trial with 50–57-year-old women. The intervention included the year-long use of either HRT preparation (2 mg 17β-estradiol, E2; 1 mg norethisterone acetate, NETA, n = 10) or placebo (CO, n = 9). Microarray technology and quantitative PCR (qPCR) were used to study the expression of insulin-like growth factor I (IGF-1) and its splice variants as well as IGF-1 receptor, Akt1, mTOR, FOXO1, FOXO3, atrog…

estradioliTranscription GeneticEndocrinology Diabetes and MetabolismMuscle Fibers SkeletalEstrogen receptorpostmenopausal womenMuscle ProteinsFOXO1Receptor IGF Type 10302 clinical medicineEndocrinologyProtein IsoformsTestosteroneInsulin-Like Growth Factor IReceptorRandomized Controlled Trials as Topic0303 health sciencesEstradiolMyogenesisForkhead Box Protein O1TOR Serine-Threonine KinasesEstrogen Replacement TherapyForkhead Box Protein O3Forkhead Transcription FactorsMiddle Agedmedicine.anatomical_structureReceptors EstrogenReceptors AndrogenFemalemedicine.medical_specialtynorethisterone acetate030209 endocrinology & metabolismBiologypostmenopausaalinen nainen03 medical and health sciencesInternal medicinemedicineHumansnoretisteroniasetaattiluurankolihasskeletal muscleMuscle SkeletalProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyhormonikorvaushoitoSKP Cullin F-Box Protein LigasesSkeletal muscleAndrogen receptorNorethindrone AcetateEndocrinologyHormone replacement therapyIGF-1 signalointiNorethindroneIGF-1 signalingProto-Oncogene Proteins c-aktGrowth hormoneIGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
researchProduct